Recent advancement in understanding of Alzheimer's disease: Risk factors, subtypes, and drug targets and potential therapeutics

被引:9
作者
Prabha, Sneh [1 ]
Sajad, Mohd [1 ]
Hasan, Gulam Mustafa [2 ]
Islam, Asimul [1 ]
Hassan, Md Imtaiyaz [1 ]
Thakur, Sonu Chand [1 ]
机构
[1] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India
[2] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj, Saudi Arabia
关键词
Alzheimer's disease; Neuroinflammation; Gut microbiome; Drug targets; Drug discovery; Amyloid plaques; MOUSE MODEL; INHIBITION; PATHOPHYSIOLOGY; LIPOXYGENASES; PATHOGENESIS; INFLAMMATION; ASSOCIATION; MECHANISMS; HYPOTHESIS; SECRETASE;
D O I
10.1016/j.arr.2024.102476
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alzheimer's disease (AD) is a significant neocortical degenerative disorder characterized by the progressive loss of neurons and secondary alterations in white matter tracts. Understanding the risk factors and mechanisms underlying AD is crucial for developing effective treatments. The risk factors associated with AD encompass a wide range of variables, including gender differences, family history, and genetic predispositions. Additionally, environmental factors such as air pollution and lifestyle-related conditions like cardiovascular disease, gut pathogens, and liver pathology contribute substantially to the development and progression of AD and its subtypes. This review provides current update and deeper insights into the role of diverse risk factors, categorizing AD into its distinct subtypes and elucidating their specific pathophysiological mechanisms. Unlike previous studies that often focus on isolated aspects of AD, our review integrates these factors to offer a comprehensive understanding of the disease. Furthermore, the review explores a variety of drug targets linked to the neuropathology of different AD subtypes, highlighting the potential for targeted therapeutic interventions. We further discussed the novel therapeutic options and categorized them according to their targets. The roles of different drug targets were comprehensively studied, and the mechanism of action of their inhibitors was discussed in detail. By comprehensively covering the interplay of risk factors, subtype differentiation, and drug targets, this review provides a deeper understanding of AD and suggests directions for future research and therapeutic strategies.
引用
收藏
页数:16
相关论文
共 143 条
  • [1] Ahuja M., 2017, Medicinal Plants and Fungi: Recent Advances in Research and Development, P3
  • [2] Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease
    Alam, Jahngeer
    Kalash, Anushka
    Hassan, Md Imtaiyaz
    Rahman, Syed Ziaur
    [J]. NEUROLOGICAL RESEARCH, 2024, 46 (04) : 318 - 325
  • [3] 2018 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (03) : 367 - 425
  • [4] A review on cholinesterase inhibitors for Alzheimer's disease
    Anand, Preet
    Singh, Baldev
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (04) : 375 - 399
  • [5] Alzheimer's Disease: An Updated Overview of Its Genetics
    Andrade-Guerrero, Jesus
    Santiago-Balmaseda, Alberto
    Jeronimo-Aguilar, Paola
    Vargas-Rodriguez, Isaac
    Ruth Cadena-Suarez, Ana
    Sanchez-Garibay, Carlos
    Pozo-Molina, Glustein
    Fabiola Mendez-Catala, Claudia
    Cardenas-Aguayo, Maria-del-Carmen
    Diaz-Cintra, Sofia
    Pacheco-Herrero, Mar
    Luna-Munoz, Jose
    Soto-Rojas, Luis O.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [6] Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan
    Baeuerl, C.
    Collado, M. C.
    Diaz Cuevas, A.
    Vina, J.
    Perez Martinez, G.
    [J]. LETTERS IN APPLIED MICROBIOLOGY, 2018, 66 (06) : 464 - 471
  • [7] Bandyopadhyay S., 2007, Role of the APP nonamyloidogenic signaling pathway and targeting -secretase as an alternative drug target for treatment of Alzheimer's disease, V14, P2848
  • [8] Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials
    Basheer, Neha
    Smolek, Tomas
    Hassan, Imtaiyaz
    Liu, Fei
    Iqbal, Khalid
    Zilka, Norbert
    Novak, Petr
    [J]. MOLECULAR PSYCHIATRY, 2023, 28 (06) : 2197 - 2214
  • [9] Amyloid-induced neurodegeneration: A comprehensive review through aggregomics perception of proteins in health and pathology
    Bashir, Sania
    Aiman, Ayesha
    Shahid, Mohammad
    Chaudhary, Anis Ahmad
    Sami, Neha
    Basir, Seemi Farhat
    Hassan, Imtaiyaz
    Islam, Asimul
    [J]. AGEING RESEARCH REVIEWS, 2024, 96
  • [10] Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
    Becker, Bruno
    Nazir, Faisal Hayat
    Brinkmalm, Gunnar
    Camporesi, Elena
    Kvartsberg, Hlin
    Portelius, Erik
    Bostrom, Martina
    Kalm, Marie
    Hoglund, Kina
    Olsson, Maria
    Zetterberg, Henrik
    Blennow, Kaj
    [J]. MOLECULAR NEURODEGENERATION, 2018, 13